Kala Bio (Kala Bio) Total Liabilities : $48.45 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Total Liabilities?

Kala Bio's Total Liabilities for the quarter that ended in Dec. 2023 was $48.45 Mil.

Kala Bio's quarterly Total Liabilities increased from Jun. 2023 ($49.01 Mil) to Sep. 2023 ($49.90 Mil) but then declined from Sep. 2023 ($49.90 Mil) to Dec. 2023 ($48.45 Mil).

Kala Bio's annual Total Liabilities declined from Dec. 2021 ($122.62 Mil) to Dec. 2022 ($67.85 Mil) and declined from Dec. 2022 ($67.85 Mil) to Dec. 2023 ($48.45 Mil).

Kala Bio Total Liabilities Historical Data

The historical data trend for Kala Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Total Liabilities Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

124.63

121.61

122.62

67.85

48.45

Kala Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															67.85	48.77	49.01	49.90	48.45

Kala Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kala Bio's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.346	+	(35.989	+	4.11
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	48.45

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	55.949	-	7.504
	=	48.45

Kala Bio's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.346	+	(35.989	+	4.11
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	48.45

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	55.949	-	7.504
	=	48.45

Kala Bio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kala Bio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (Kala Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Executives

Todd Bazemore	officer: Chief Operating Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell	officer: Chief Medical Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg	officer: See Remarks	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi	officer: CHIEF BUSINESS OFFICER	C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki	director, officer: Chief Executive Officer	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth	officer: Chief Financial Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid	director	C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen	officer: Chief Scientific Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg	director	100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116